Immune checkpoint inhibitors as neoadjuvant therapy in early triple-negative breast cancer: A systematic review and meta-analysis

Conclusions: PD-1/PDL-1 inhibitors in combination with neoadjuvant chemotherapy for early TNBC show significant improvement in pCR irrespective of PDL-1 status and cancer stage.

Source: Journal of Cancer Research and Therapeutics - November 16, 2022 Category: Cancer & Oncology Authors: Niti Mittal Surjit Singh Rakesh Mittal Jyoti Kaushal Vivek Kaushal Source Type: research